^
Association details:
| Biomarker: | NCOR2-NTRK1 fusion + TMB-H |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
Published date:
04/17/2021
Excerpt:
...we reported a 60-year-old female diagnosed with advanced lung adenocarcinoma. NGS-based molecular profiling identified a novel NCOR2-NTRK1 fusion and high tumor mutational burden (TMB) (58.58 mutations/Mb) in this case....The patient received treatment with anti-PD-1 immune checkpoint inhibitor of camrelizumab. After two cycles of treatment, the CT scan showed some tumor nodules were still enlarged, indicating disease progression.
DOI:
https://doi.org/10.1186/s12890-021-01490-x
